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Mitochondrial (mt) impairment, particularly within complex I of the electron transport system, has been implicated
in the pathogenesis of Parkinson disease (PD). More than half of mitochondrially encoded polypeptides form part
of the reduced nicotinamide adenine dinucleotide dehydrogenase (NADH) complex I enzyme. To test the hypothesis
that mtDNA variation contributes to PD expression, we genotyped 10 single-nucleotide polymorphisms (SNPs)
that define the European mtDNA haplogroups in 609 white patients with PD and 340 unaffected white control
subjects. Overall, individuals classified as haplogroup J (odds ratio [OR] 0.55; 95% confidence interval [CI]
0.34–0.91; ) or K (OR 0.52; 95% CI 0.30–0.90; ) demonstrated a significant decrease in risk ofPp .02 Pp .02
PD versus individuals carrying the most common haplogroup, H. Furthermore, a specific SNP that defines these
two haplogroups, 10398G, is strongly associated with this protective effect (OR 0.53; 95% CI 0.39–0.73; Pp
). SNP 10398G causes a nonconservative amino acid change from threonine to alanine within the NADH.0001
dehydrogenase 3 (ND3) of complex I. After stratification by sex, this decrease in risk appeared stronger in women
than in men (OR 0.43; 95% CI 0.27–0.71; ). In addition, SNP 9055A of ATP6 demonstrated a protectivePp .0009
effect for women (OR 0.45; 95% CI 0.22–0.93; ). Our results suggest that ND3 is an important factor inPp .03
PD susceptibility among white individuals and could help explain the role of complex I in PD expression.
Introduction
Selective degeneration of dopaminergic neurons within
the substantia nigra (SN) manifests in the clinical signs
of Parkinson disease (PD [MIM 168600]), including
resting tremor, rigidity, gait disturbances, and brady-
kinesia. The etiology of idiopathic PD is currently un-
defined; however, it is now largely accepted that genetic
susceptibility factors exist and may interact with envi-
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ronmental exposures, leading to the development of this
late-onset degenerative disease.
Several reports suggest that mitochondrial (mt) dys-
function may be involved in the expression of PD
(Greenamyre et al. 1999, 2001). The activity of complex
I, which is the first complex of the electron transport
chain, has been reported to be reduced within SN tissue
and platelets of patients with PD, an observation sug-
gestive of a systemic defect (Parker et al. 1989; Schapira
et al. 1989, 1990). Furthermore, biochemical analyses,
using cytoplasmic hybrid cells (cybrids), have demon-
strated moderate impairment of complex I in patients
with sporadic PD, indicating that mtDNA aberrations
may cause the deficit in energy production (Swerdlow
et al. 1996; Gu et al. 1998). In these cybrid systems,
several other pathological events were observed, in-
cluding excessive generation of reactive oxygen species
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Table 1
Characterization of European Haplogroups
HAPLOGROUP
SNP
1719 4580 7028 8251 9055 10398 12308 13368 13708 16391
H … … C … … A … … … …
I A … T A … G … … … A
J … … T … … G … … A …
K … … T … A G G … … …
T … … T … … A … A … …
U … … T … … A G … … …
V … A T … … A … … … …
W … … T A … A … … … …
X A … T … … A … … … …
(ROS), which leads to oxidative stress (Swerdlow et al.
1996; Cassarino et al. 1997), increased expression of
antioxidative proteins (bcl-2 and bcl-XL), signaling a
reaction to cell stress (Veech et al. 2000) and the creation
of abnormal mitochondria morphology with protein in-
clusion bodies (Trimmer et al. 2000). In addition, ani-
mal models have shown that environmental toxins that
inhibit complex I activity cause clinical manifestations
of PD (Betarbet et al. 2002). A seminal study by Betarbet
and colleagues (2000) provided compelling evidence of
this causal relationship in rat model experiments that
involved chronic exposure to the pesticide rotenone. In
the same study, Betarbet and colleagues showed that
inhibition of complex I by rotenone caused the selective
degeneration of SN dopaminergic neurons, accumula-
tion of ubiquitin, and a-synuclein–positive cytoplasmic
inclusions, as well as development of tremor and rigidity
within subjects. Furthermore, the pathological findings
were replicated in an in vitro model that provided ev-
idence of molecular mechanisms that may lead to grad-
ual neuronal cell death that is reminiscent of PD (Sherer
et al. 2002). Accordingly, these studies support the hy-
pothesis that changes in complex I could contribute to
a primary pathogenic susceptibility mechanism in PD.
Interestingly, seven of the polypeptides encoded by
the mt genome are also known to code for protein sub-
units of complex I. We hypothesize that genetic poly-
morphisms within the mt genome could act as suscep-
tibility factors and contribute to the expression of PD,
either directly or through interactions with nuclear en-
coded genes or environmental toxins. To test the hy-
pothesis that mt variation contributes to this expression,
we genotyped predefined European mtDNA haplo-
groups (Torroni et al. 1996) in a large study of white
patients with PD and white unaffected control subjects
(table 1).
Subjects and Methods
Sample
A total of 609 unrelated patients of European ancestry
who had PD were included in the present study. Cases
were ascertained through the Morris K. Udall Parkin-
son’s Disease Center of Excellence, Duke Center for Hu-
man Genetics (DCHG), and from the DCHG/Glaxo-
SmithKline Parkinson’s Disease Genetics Collaboration.
The 340 white control subjects were collected from
spouses of patients with Alzheimer disease ascertained
through the Joseph and Kathleen Bryan Alzheimer’s Dis-
ease Research Center. Control subjects had no significant
signs of cognitive or neurological impairment when en-
rolled in the study. Mean  SD age at onset (AAO) in
affected individuals in the sample is 62 years 12. AAO
is self-reported by the patient with PD and is defined as
the age at which the affected individual first noticed one
of the cardinal signs of PD. Mean  SD age at exam-
ination (AAE) of patients with PD is 66 years 12, and
mean  SD AAE of control subjects is 69 years  9.
AAE was defined as the age at which the affected or
unaffected participant was clinically examined by study
personnel. The overall sample consists of 57% males
and 43% females. The PD case group is composed of
63% men and 37% women, whereas the control group
consists of 44% men and 56% women. Written consent
was obtained from all participants, in accordance with
protocols approved by the institutional review board at
each contributing center. A board-certified neurologist
specializing in movement disorders or a physician assis-
tant experienced in neurological disorders examined in-
dividuals, and rigorous clinical criteria were used for
diagnosis of PD. All patients with PD had at least two
principal signs of PD (resting tremor, bradykinesia, or
rigidity) and no clinical features of any other parkin-
sonian syndrome.
Classification of Haplogroups
Ten SNPs within coding genes and the control region
were chosen for genotyping, according to the previous
work of Torroni et al. (1996). SNPs within RFLP sites
were identified so that the allelic discrimination method
Taqman could be employed (table 1). By comparing the
complete, revised Cambridge genomic sequence (An-
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drews et al. 1999) with the Japanese (Anderson et al.
1981), Swedish (Arnason et al. 1996), and African
(Horai et al. 1995) reference sequence genomes, we were
able to identify the nucleotide change within each re-
striction site (GenBank). All primer and probe sequences
are available upon request.
SNP Genotyping
Genomic DNA was isolated from whole blood sam-
ples by the DCHG DNA banking core facility, using
Puregene (Gentra Systems). High-throughput genotyp-
ing was established using the 5′ nuclease allelic discrim-
ination Taqman assay in a 384-well format on the ABI
Prism 7900HT Sequence Detection System (Applied
Biosystems). In each chamber of the 384-well sample
plates, 20 ng of DNA was distributed using a Hydra
HTS Workstation microdispensing system (Robbins Sci-
entific). Probes and primers for each SNP were designed
using ABI Prism Primer Express software, version 2.0
(Applied Biosystems). All probes designed with a black-
hole quencher reporter were generated by Integrated
DNA Technologies, and all minor-groove–binding Taq-
man probes were manufactured by Applied Biosystems.
To each well, 5 ml of master mix (0.2 U/ml Taqman
Universal PCR Master Mix; 0.9 ng/ml of each forward
and reverse primer; and 0.2 ng/ml of each probe) was
dispensed by a MultiProbe2 204DT (Packard Instru-
ments). The amplification reaction was conducted on a
384-well ABI Dual GeneAmp PCR System 9700, util-
izing the following program: 50C for 2 min, 95C for
10 min, 95C for 15 s, and 62C for 1 min, repeated
for 40 cycles; samples were held at 4C after cycling
completion. Data were generated on an ABI Prism
7900HT Sequence Detection System (SDS) and were an-
alyzed using the associated SDS, version 2.0, software.
The few samples that fell outside SNP clusters were
sequenced for genotyping. Sequencing primers were de-
signed using the Vector NTI Suite 6 software package
(InforMax) and the Primer3 Web site. DNA sequencing
was conducted on an ABI Prism 3100 Genetic Analyzer
(Applied Biosystems). Sequencing analysis was per-
formed using the ABI Prism Sequencing Analysis soft-
ware, version 3.7, and Sequencher software, version
4.0.5. In addition to the positive control samples, four
negative control samples were assayed per plate. For
quality control, samples from 24 individuals were du-
plicated on each 384-well plate. Technicians performing
the SNP genotyping were blinded to the duplications. In
addition, two DNA samples from the CEPH were se-
quenced for each SNP, were tested eight times per plate,
and were also used as blind internal controls. All quality-
control samples were compared in the Duke Center for
Human Genetics Data Coordinating Center. Data were
stored and managed by the PEDIGENE system (Haynes
et al. 1995).
Statistical Analysis
All statistical analyses were performed using SAS soft-
ware, release 8.1 (SAS Institute). Statistical significance
was declared at a p .05. A t test was conducted to
evaluate differences in AAE between case and control
subjects, with a significant difference found (Pp
). To assess differences in distribution of sex be-.0001
tween cases and controls, we used a x2 test and found
a significant difference ( ). Therefore, to adjustPp .0001
for potential confounding, we used AAE and sex as co-
variates in the analyses. We performed unconditional
logistic regression to generate ORs with their associated
95% CIs, to assess odds of carrying each mt SNP in PD
cases compared with controls. In addition, we used un-
conditional logistic regression to simultaneously assess
odds of PD cases carrying specific haplogroups. Since
haplogroup carrier status was a categorical independent
variable with more than two categories, there are mul-
tiple ways to assign the reference group: each haplo-
group can be compared with a common haplogroup, or
each haplogroup can be compared with all other hap-
logroups pooled into one group. An advantage of using
a common haplogroup as the reference is that it is more
homogeneous than a pooling of different haplogroups,
and it means that each haplogroup is compared with the
same reference group for consistency. We performed the
analysis, using both approaches for comparison. First,
H was chosen as a reference group, since it is found at
the highest frequency (40%–50%) among European
populations. We also tested for association of a specific
haplogroup (e.g., K) relative to all other haplogroups,
by pooling frequencies of non-K. This is conceptually
the same as the binary SNP allele comparison. P values
reported for SNPs and haplogroups are based on the
Wald x2 statistic for the particular SNP or haplogroup
and are not adjusted for multiple testing.
Results
All nine major European haplogroups were observed in
our sample and did not differ significantly from a pre-
vious study of a similar North American control pop-
ulation (Torroni et al. 1994) (table 2). In addition, a
nearly identical percentage of individuals (8.2% in con-
trol subjects and 8.5% in patients with PD) did not fit
into these nine predefined haplogroups and were clas-
sified as “others.” This group most likely consists of rare
European haplogroups (e.g., R or Z) or the historical
admixture known to exist in the North American white
population (Finnila et al. 2000; Richards et al. 2000).
Therefore, comparison of overall population haplo-
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Table 2
Haplogroup Counts and Frequencies Overall
HAPLOGROUP
PD
( )Np 609
CONTROL
( )Np 340
TOTAL
( )Np 949
n % n % n %
H 273 44.8 134 39.4 407 42.9
I 20 3.3 11 3.2 31 3.3
J 43 7.1 38 11.2 81 8.5
K 34 5.6 32 9.4 66 6.9
T 53 8.7 36 10.6 89 9.4
U 94 15.4 41 12.1 135 14.2
V 24 3.9 10 2.9 36 3.6
W 8 1.3 5 1.5 13 1.4
X 8 1.3 5 1.5 13 1.4
Other 52 8.5 28 8.2 80 8.4
Table 3
OR of mt Haplogroups and SNPs Overall
mt VARIANT OR
95% CI
P
Lower
Boundary
Upper
Boundary
Haplogroup:
I .83 .38 1.83 .65
J .55 .34 .91 .02
K .52 .30 .90 .02
T .74 .46 1.21 .23
U 1.24 .81 1.92 .33
V 1.19 .54 2.62 .67
W .67 .20 2.11 .48
X .59 .18 1.90 .37
Other .90 .53 1.51 .69
SNP:
1719GA 1.30 .77 2.21 .33
4580GA .74 .34 1.59 .44
7028TC .83 .63 1.09 .18
8251GA 1.05 .58 1.89 .88
9055GA .69 .44 1.09 .11
10398GA .53 .39 .73 .0001
12308AG 1.04 .75 1.45 .80
13368AG 1.26 .80 1.98 .31
13708GA .72 .47 1.11 .14
16391AG 1.06 .49 2.29 .88
Total sample consists of 949 total individuals, ofwhom
609 are patients with PD. OR for each haplogroup was
established by comparison with reference haplogroup H.
groups suggests that the control population was well
matched to our PD cases, and it supports an absence of
significant substructure (see the “Discussion” section).
Evaluation of genotyping results, by use of the Taq-
man method, revealed 100% match of all duplications.
Although heteroplasmy was not specifically tested, we
did not observe the occurrence of multiple mtDNA cop-
ies (wild type or mutant) in any individual sequenced
( ).Np 125
The frequencies of both haplogroup J (OR 0.55; 95%
CI 0.34–0.91; ) and haplogroup K (OR 0.52;Pp .02
95% CI 0.31–0.90; ) were lower in PD casesPp .02
than in controls when each group was compared with
the common haplogroup H (table 3 fig. 1). A similar
finding ( ) was revealed when each haplogroupPp .03
was analyzed by comparing it with all other haplo-
groups pooled together (data not shown). In a com-
parison designed to determine what made these two
haplogroups (J and K) uniquely different from the other
haplogroups tested, one SNP located at position 10398
was identified. We therefore tested this SNP indepen-
dently and found that the difference in 10398G allele
frequency between patients with PD and control sub-
jects was highly significant (OR 0.53; 95% CI 0.39–
0.73; ). The 10398G allele causes a noncon-Pp .0001
servative amino acid change from threonine (Thr) (hy-
drophilic) to alanine (Ala) (hydrophobic) within the
NADH dehydrogenase 3 (ND3) gene, which is a subunit
of complex I. Further stratification of the data set by
sex revealed that the 10398G effect appeared to be
stronger in women (OR 0.43; 95% CI 0.27–0.71;
) than in men (OR 0.62; 95% CI 0.41– 0.97;Pp .0009
). Moreover, this analysis showed that SNPPp .04
9055A, found within the ATP6 gene, has a mild pro-
tective effect only among women (OR 0.46; 95% CI
0.22–0.91; ) (table 3; fig. 2). In addition,Pp 0.03
we found that SNP allele 13708A, located within
the NADH dehydrogenase 5 (ND5) gene, is protec-
tive in the group 70 years of age (OR 0.27; 95%
CI 0.09–0.77; ). All other SNPs used for con-Pp .01
structing the haplotypes failed to reach significance for
association in the overall and stratified data sets.
Discussion
The mechanism(s) of mt dysfunction observed experi-
mentally in PD has not yet been explained. Here, we
present evidence for the involvement of specific inherited
mt haplogroups and SNPs in conferring both risk of and
protection from the common form of PD.
In association studies, population stratification could
lead to false associations between gene markers and
disease. However, we were careful to match cases and
controls for ethnic background during clinical evalua-
tion, and specific mt haplogroups matched well with
previous studies of North American white populations
(table 2) (Torroni and Wallace 1994). Given that the
“European” haplogroup frequencies have been well doc-
umented, the similarity of haplogroup proportions in our
control population to those in other studies supports
the conclusion that this control and PD group are rep-
resentative of the general white population. Further-
more, a recent study regarding population subdivision
has suggested that carefully matched case-control sam-
ples in U.S. and European populations, like those pre-
sented here, are “unlikely to contain levels of structure
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Figure 1 OR of individual mt haplogroup for risk of PD.  indicates results for both sexes combined; ● denotes results for women; 
denotes results for men. Bars indicate 95% CIs. CL p confidence limit.
that would result in significantly inflated numbers of
false-positive associations” (Ardlie et al. 2002). The eti-
ology of the apparent protective effect of the J and K
haplogroups and the 10398G polymorphism contained
within them is not yet known, although the association
suggests a significant biological role. Indeed, the pro-
tective effect of the J haplogroup is interesting, given
the published association between J and longevity in
northern Italian men (De Benedictis et al. 1999, 2000).
Conversely, haplogroup J has also been associated with
increased risk for expression of a maternally inherited
blindness disorder (Leber hereditary optic neuropathy)
(Brown et al. 2002).
Both associated polymorphisms (10398G and
13708A) cause nonconservative amino acid changes
from Thr to Ala within ND3 and fromAla to Thrwithin
ND5. These subunits are two of the seven mt-encoded
peptides making up the 43 enzymatic subunits of com-
plex I.
Several possible mechanisms for the apparent pro-
tective effect of the associated alleles are possible. Given
the biological role of complex I, it is conceivable that
the strongly associated 10398G allele may increase the
performance of complex I within the brain and other
tissues in individuals derived from J and K haplogroup
lineages. This may be specifically advantageous to the
functioning of the complex I in a normal state or under
abnormal oxidative stress conditions. Individuals who
inherit alternative genotypes that are not protective (or
are mildly deleterious) may have inadequate capability
for energy metabolism when under cellular stress and
thus be at greater risk for developing PD.
Alternatively, the associated 10398 SNP may act as
a surrogate marker for a causative variation. For in-
stance, a variation may reside in an mt gene and be in
linkage disequilibrium with 10398. One other haplo-
group (I) carrying 10398G did not give the same sig-
nificant findings as haplogroups J and K. Although I, J,
and K all share the 10398G polymorphism, their evo-
lutionary relationships are clearly divergent in a phy-
logeny of mt lineages whereby an ArG substitution has
reoccurred at that position several times throughout hu-
man evolution (Herrnstadt et al. 2002). Haplogroup I
may lack the apparent protective effect, because of the
presence of other polymorphisms that are not shared
with J and K. However, the frequency of I is relatively
low (3%), which reduced the power of the analysis to
detect association, even if it was present.
An additional explanation for the pathological mech-
anism of the 10398 polymorphism is that the 10398A
allele may cause a greater ROS production than
10398G. Complex I normally produces ROS during
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Figure 2 OR results of each SNP for risk of PD.  indicates results for both sexes combined; ● denotes results for women;  denotes
results for men. Bars indicate 95% CIs. CL p confidence limit.
cellular activity; however, when the complex is com-
promised or inhibited, generation of ROS is enhanced,
leading to oxidative stress (Orth and Schapira 2002).
Lipids, proteins, and DNA within SN tissue are partic-
ularly susceptible to oxidative damage (Jenner and
Olanow 1998). It has been proposed that excessive ox-
idative stress over time may be one of the mechanisms
responsible for the degeneration of SN neurons and the
concomitant accumulation of fibrillar proteins (Betarbet
et al. 2000; Sherer et al. 2002). Therefore, the toxic
effects resulting from oxidative injury caused by
mtDNA polymorphisms plus environmental exposure
to pesticides (rotenone or other xenotoxins) could act
synergistically to cause PD.
Our data demonstrated that the apparent protective
effect of the 10398G allele was stronger among the
women ( ) than among the men ( ).Pp .0009 Pp .04
Furthermore, SNP allele 9055A, which partly defines
haplogroup K, was found to decrease PD risk only in
women. These findings are interesting, given the results
from multiple clinical studies showing that incidence of
PD among men is higher than that among women (male:
female ratio 1.5–2.5:1.0) (Tanner and Goldman 1996;
Swerdlow et al. 2001). Therefore, our results suggest a
possible rationale for the higher susceptibility observed
among women.
Interestingly, a previous study also demonstrated that
the 10398G polymorphism was found at an increased
frequency in a control population when compared with
patients with PD (Simon et al. 2000). Although this
difference was statistically significant ( ), thePp .001
authors correctly dismissed their findings, because their
control group was not ethnically matched to the white
cases. Allele 10398G is found in only 26% of white
individuals, whereas it is found at greater frequencies
in Asians (66%) and sub-Saharan Africans (91%–96%)
(Torroni and Wallace 1994; Wallace et al. 1999). Since
their control group was ethnically mixed, the frequency
difference could have resulted from this known differ-
ence in population substructure. This contrasts with our
study, in which case-control samples were ethnically
matched. Therefore, additional population studies will
be needed to confirm the protective effect of 10398G
allele in white populations.
However, the findings of Simon et al. (2000) raise the
intriguing observation that the allele frequency of
10398A (risk allele) among populations appears to cor-
respond to the trends in PD prevalence worldwide, in
that disease is believed to be most common in white
individuals, who have a higher frequency of this risk
allele (10398A), than in members of other major ethnic
groups (Muthane et al. 2001).
810 Am. J. Hum. Genet. 72:804–811, 2003
Concerning the applicability of the results in other
general, ethnically mixed populations, if the 10398G
allele is the major functional contributor to the observed
association effect, then we would expect the effect to
be similar in all individuals carrying this allele. How-
ever, we cannot rule out potential interactions with
other white mt or nuclear genes, and our finding there-
fore applies only to white individuals from Europe and
North America. Further studies in other ethnic groups
will be needed to evaluate the protective effect of
10398G.
Although there is a growing body of evidence to sup-
port the role of mtDNA in the pathogenesis of PD, few
gains have been made in the discovery of causative or
risk alleles. Our findings may help elucidate the mech-
anism behind the mt dysfunction found in patients with
PD, as well as contribute to the understanding of why
a higher disease prevalence is reported in white indi-
viduals and in men. In addition, these data provide the
basis for the exploration of gene-gene or gene-environ-
ment interactions that may affect pathogenesis of PD.
Future biochemical studies will be needed to confirm
the functional significance of these associations.
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